Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Status:	Completed
Conditions:	HIV / AIDS
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	2 - Any
Updated:	1/3/2019
Start Date:	February 1, 2017
End Date:	December 14, 2018

An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency

This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate
safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary
immunodeficiency (PID). A total of 45 subjects (including at least 14 [30%] pediatric
subjects ≤ 17 years of age and at least 9 [20%] obese subjects with body mass index [BMI] of
≥30 kg/m2) with confirmed PID will be evaluated in the study. The study will include three
cohorts of 15 subjects each as follows: i) Pump-Assisted Volume Cohort (weekly infusions),
volume per injection site of 25 mL up to 50 mL, ii) Pump Assisted Flow Rate Cohort (weekly
infusions), flow rate per injection site of 25 mL/hour up to 100 mL/hour, iii) Manual Push
Flow Rate Cohort (2 to 7 infusions per week), flow rate per injection site of 25 to 30
mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute). Each
cohort will test 3 infusion parameter levels (4 for the pump-assisted flow rate cohort),
repeated at least 4 times over a duration of 12 weeks (16 weeks for the flow rate cohort).
After 4 infusion weeks at each level, qualifying subjects (responders) will switch to the
next infusion parameter level (eg, from 25 to 50 mL/h). During the study, the weekly dose
will remain unchanged (as prescribed by treating physician, usually within 100-200 mg/kg per
week range); only the respective infusion parameter under evaluation will change.

Inclusion Criteria:

- Male or female on stable dose of IgPro20 (Hizentra) therapy.

- Women of childbearing potential must be using and agree to continue using medically
approved contraception (which must be discussed with the study doctor) and must have a
negative pregnancy test at screening.

- Subjects with PID, eg, with a diagnosis of common variable immunodeficiency or
X-linked agammaglobulinemia, as defined by the Pan American Group for Immune
Deficiency and the European Society of Immune Deficiencies.

- With infusion parameters as specified below:

Pump-Assisted Flow Rate Cohort subjects only

- Experience with pump-assisted infusions of IgPro20 at the tolerated flow rate of 25
mL/h per injection site for at least 1 month prior to Day 1.

Pump-Assisted Volume Cohort subjects only

- Total weekly IgPro20 dose of ≥ 50 mL (≥ 10 g).

- Experience with pump-assisted infusions of IgPro20 at tolerated volumes of 25
mL/injection site for at least 1 month prior to Day 1.

Manual Push Flow Rate Cohort subjects only

- Experience with frequent (2-7 times per week) infusions of IgPro20 at the tolerated
flow rate of approximately 0.5 mL/min (equivalent of 25-30 mL/h) per injection site
for at least 1 month prior to Day 1. The dose (volume) per injection site should not
exceed 25 mL.

Exclusion Criteria:

- Ongoing serious bacterial infections at the time of screening.

- Other significant medical conditions that could increase the risk to the subject.

- Females who are pregnant, breast feeding, or planning a pregnancy during the course
study.

- Participation in a study with an Investigational Medicinal Product (IMP) other than
IgPro20 within three months prior to enrollment.

We found this trial at

sites

The Ottawa Hospital

1967 Riverside Drive
Ottawa, Ontario K1H 7W9

Principal Investigator: Juthaporn Cowan, MD

from

Ottawa,